The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Multispecific antibody shows promise for B cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Nutcracker Therapeutics Inc., a biotechnology company focused on developing RNA therapies through its proprietary technology platform, presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Columvi combination extends OS in transplant-ineligible R/R DLBCL in phase III trial

In the phase III STARGLO study of Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy, the Columvi regiment extended overall survival.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account